Longeveron Inc. Delivers Corporate Update and Reveals Third Quarter 2022 Financial Results: A Look into the Future of Biotechnology
Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results Achieving Clinical and Regulatory Milestones Longeveron Inc. has achieved key clinical and regulatory milestones across its clinical pipeline. One notable accomplishment is the completion of enrollment in Longeveron’s Phase 2a trial for Alzheimer’s Disease. This milestone marks a significant step forward in the…